Tags

Type your tag names separated by a space and hit enter

Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011.
Diagn Microbiol Infect Dis. 2014 Apr; 78(4):437-42.DM

Abstract

The Assessing Worldwide Antimicrobial Resistance Evaluation Program monitors the activity of ceftaroline and comparator agents tested against pathogens causing either respiratory or skin and soft tissue infections. A total of 7733 isolates from patients in 80 medical centers across the United States (USA) identified as respiratory tract pathogens by the infection type and/or specimen site recorded by the submitting laboratory during 2009-2011 were evaluated. There were 3360 isolates of Streptococcus pneumoniae, 1799 Haemophilus influenzae, 1087 Staphylococcus aureus, 678 Moraxella catarrhalis, 459 Klebsiella pneumoniae, 223 Escherichia coli, and 127 Klebsiella oxytoca. Annual penicillin resistance among S. pneumoniae ranged from 21.9 to 24.3%. All S. pneumoniae strains were inhibited at a ceftaroline MIC of ≤0.5 μg/mL with 100.0% of isolates categorized as susceptible. Ceftaroline was 16-fold more active than ceftriaxone and 32-fold more active than amoxicillin-clavulanate against penicillin-resistant pneumococci. Only 49.8% of the penicillin-resistant isolates were susceptible to ceftriaxone. There were a total of 1087 S. aureus (48.9% methicillin-resistant S. aureus [MRSA]) isolates, and the yearly MRSA rate ranged from 47.9 to 49.7%. The ceftaroline MIC50/90 for S. aureus was at 0.25/1 μg/mL; 98.2% susceptible and no resistant strains (≥4 μg/mL). Ceftaroline activity against methicillin-susceptible S. aureus (MSSA) isolates (MIC50 and MIC90, 0.25 and 0.25 μg/mL, respectively; 100% susceptible) was 2- to 4-fold greater than for MRSA (MIC50/90, 0.5/1 μg/mL; 96.2% susceptible). The ceftriaxone MIC90 for MSSA was 4 μg/mL. Ceftaroline was active against H. influenzae (MIC50/90 ≤0.015/0.03 μg/mL; 100.0% susceptible) and against M. catarrhalis (MIC50/90, 0.06/0.12 μg/mL). Ceftaroline was active against non-extended spectrum β-lactamase (ESBL) phenotype strains of Enterobacteriaceae but not against ESBL-positive phenotype strains. In summary, ceftaroline was highly active against a large collection of bacterial pathogens isolated from patients with respiratory tract infections in the USA during 2009 through 2011.

Authors+Show Affiliations

JMI Laboratories, North Liberty, IA 52317, USA. Electronic address: robert-flamm@jmilabs.com.JMI Laboratories, North Liberty, IA 52317, USA.JMI Laboratories, North Liberty, IA 52317, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24582578

Citation

Flamm, Robert K., et al. "Ceftaroline Activity Against Organisms Isolated From Respiratory Tract Infections in USA Hospitals: Results From the AWARE Program, 2009-2011." Diagnostic Microbiology and Infectious Disease, vol. 78, no. 4, 2014, pp. 437-42.
Flamm RK, Sader HS, Jones RN. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011. Diagn Microbiol Infect Dis. 2014;78(4):437-42.
Flamm, R. K., Sader, H. S., & Jones, R. N. (2014). Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011. Diagnostic Microbiology and Infectious Disease, 78(4), 437-42. https://doi.org/10.1016/j.diagmicrobio.2013.10.020
Flamm RK, Sader HS, Jones RN. Ceftaroline Activity Against Organisms Isolated From Respiratory Tract Infections in USA Hospitals: Results From the AWARE Program, 2009-2011. Diagn Microbiol Infect Dis. 2014;78(4):437-42. PubMed PMID: 24582578.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011. AU - Flamm,Robert K, AU - Sader,Helio S, AU - Jones,Ronald N, Y1 - 2013/11/06/ PY - 2013/09/25/received PY - 2013/10/22/revised PY - 2013/10/27/accepted PY - 2014/3/4/entrez PY - 2014/3/4/pubmed PY - 2014/11/5/medline KW - AWARE KW - Ceftaroline KW - S. pneumoniae KW - USA SP - 437 EP - 42 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 78 IS - 4 N2 - The Assessing Worldwide Antimicrobial Resistance Evaluation Program monitors the activity of ceftaroline and comparator agents tested against pathogens causing either respiratory or skin and soft tissue infections. A total of 7733 isolates from patients in 80 medical centers across the United States (USA) identified as respiratory tract pathogens by the infection type and/or specimen site recorded by the submitting laboratory during 2009-2011 were evaluated. There were 3360 isolates of Streptococcus pneumoniae, 1799 Haemophilus influenzae, 1087 Staphylococcus aureus, 678 Moraxella catarrhalis, 459 Klebsiella pneumoniae, 223 Escherichia coli, and 127 Klebsiella oxytoca. Annual penicillin resistance among S. pneumoniae ranged from 21.9 to 24.3%. All S. pneumoniae strains were inhibited at a ceftaroline MIC of ≤0.5 μg/mL with 100.0% of isolates categorized as susceptible. Ceftaroline was 16-fold more active than ceftriaxone and 32-fold more active than amoxicillin-clavulanate against penicillin-resistant pneumococci. Only 49.8% of the penicillin-resistant isolates were susceptible to ceftriaxone. There were a total of 1087 S. aureus (48.9% methicillin-resistant S. aureus [MRSA]) isolates, and the yearly MRSA rate ranged from 47.9 to 49.7%. The ceftaroline MIC50/90 for S. aureus was at 0.25/1 μg/mL; 98.2% susceptible and no resistant strains (≥4 μg/mL). Ceftaroline activity against methicillin-susceptible S. aureus (MSSA) isolates (MIC50 and MIC90, 0.25 and 0.25 μg/mL, respectively; 100% susceptible) was 2- to 4-fold greater than for MRSA (MIC50/90, 0.5/1 μg/mL; 96.2% susceptible). The ceftriaxone MIC90 for MSSA was 4 μg/mL. Ceftaroline was active against H. influenzae (MIC50/90 ≤0.015/0.03 μg/mL; 100.0% susceptible) and against M. catarrhalis (MIC50/90, 0.06/0.12 μg/mL). Ceftaroline was active against non-extended spectrum β-lactamase (ESBL) phenotype strains of Enterobacteriaceae but not against ESBL-positive phenotype strains. In summary, ceftaroline was highly active against a large collection of bacterial pathogens isolated from patients with respiratory tract infections in the USA during 2009 through 2011. SN - 1879-0070 UR - https://www.unboundmedicine.com/medline/citation/24582578/Ceftaroline_activity_against_organisms_isolated_from_respiratory_tract_infections_in_USA_hospitals:_results_from_the_AWARE_Program_2009_2011_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(13)00582-8 DB - PRIME DP - Unbound Medicine ER -